Target intelligence / Profile preview

Proteoglycans synthesis

Molecular classification
Glycoprotein (as subclass), Extracellular matrix molecule, Not an enzyme, receptor, or transporter
01

Overview

Proteoglycans synthesis refers to a multistep biological process in which specific enzymes assemble core proteins and glycosaminoglycan (GAG) chains to generate proteoglycans—heterogeneous macromolecules that are major structural and functional components of the animal extracellular matrix. Synthesized in the endoplasmic reticulum and Golgi apparatus, their production involves sequential action by glycosyltransferases and sulfotransferases. Proteoglycans play crucial roles in tissue structure, hydration, cell adhesion, mechanosignaling, and regulation of growth factor bioavailability. Dysregulated proteoglycan synthesis or degradation is implicated in cancer, cardiovascular disease, connective tissue disorders such as Ehlers–Danlos syndrome, and inherited lysosomal storage disorders (mucopolysaccharidoses).

Other names
Proteoglycan biosynthesisglycosaminoglycan biosynthesis pathwayPG synthesis
02

Mechanism of action

Enzyme inhibition (e.g., targeting glycosyltransferases, sulfotransferases, or heparanase to modulate glycosaminoglycan assembly and proteoglycan degradation); Anticoagulation (e.g., heparin binds antithrombin through specific glycosaminoglycan arrangements)

03

Biological functions

Extracellular matrix organizationCell adhesionSignal transduction (via interactions with growth factors and receptors)Tissue hydration and resilienceMorphogenesisCell proliferation, migration, and differentiation
04

Disease associations

Cancer (altered proteoglycan composition in tumor microenvironment)Cardiovascular disease (matrix structure and function)Connective tissue disorders (e.g., Ehlers–Danlos syndrome)Mucopolysaccharidoses (genetic lysosomal storage diseases)Inflammation
05

Safety considerations

Off-target effects due to widespread roles of proteoglycans in normal tissue functionTissue remodeling and abnormal matrix stiffness if synthesis is alteredRisk of bleeding (anticoagulant therapy with heparin)
06

Interacting drugs

Indirectly: Heparin (targets/provides glycosaminoglycan chains)

1 more in the full profile.

07

Biomarkers

Proteoglycan expression levels (e.g., syndecan, perlecan in cancer and cardiovascular disease)Specific enzyme activities (e.g., lysosomal enzymes in mucopolysaccharidoses)

Beyond the preview

Go deeper on Proteoglycans synthesis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteoglycans synthesis.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call